Understanding Obesity as a Chronic Disease
Obesity affects over 40% of adults in the U.S., driving risks for hypertension, heart failure, coronary artery disease, and dyslipidemia. It's not simply a matter of willpower but a multifactorial chronic condition influenced by genetics, environment, medications, and lifestyle. Traditional approaches like caloric deficits, high-protein/fiber diets, and exercise provide modest results, while older drugs such as phentermine, orlistat, and naltrexone/bupropion offer limited, short-term benefits.
Enter GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and dual GLP-1/GIP agonists like tirzepatide (Mounjaro, Zepbound). These injectable therapies mimic gut hormones to suppress appetite, slow gastric emptying, and improve insulin sensitivity, leading to 15-22% average weight loss in trials. However, a critical question persists: how long does this weight loss last after discontinuation? Studies show regain is common, reinforcing the need for lifelong management.
How GLP-1 and GLP-1/GIP Agonists Promote Weight Loss
GLP-1 agonists like semaglutide activate receptors in the brain and gut, signaling fullness and reducing food intake by up to 20-30%. Tirzepatide adds GIP agonism, enhancing fat metabolism and energy expenditure for superior results. Both improve cardiometabolic markers, but their effects wane without ongoing use due to the body's adaptive hunger signals.
Obesity relapse post-treatment mirrors addiction recovery: physiological drives resurface without intervention.
Tirzepatide: Evidence from the SURMOUNT-4 Trial
The phase 3 SURMOUNT-4 trial (NCT04660643), led by Louis Aronne et al., provides the strongest data on tirzepatide maintenance. It enrolled 670 adults with overweight or obesity (no diabetes) who first completed a 36-week open-label tirzepatide lead-in at maximum tolerated doses (5-15 mg weekly). Participants achieved 20.9% mean weight loss—translating to about 50 pounds for a 240-pound person.
They were then randomized to continue tirzepatide (n=335) or switch to placebo (n=335) for 52 more weeks (total 88 weeks). Results were stark:
- Tirzepatide group: Additional 5.5% loss (total ~25.3% from baseline).
- Placebo group: 14% regain from their week-36 low, erasing most gains.
Clinical context: This highlights tirzepatide's dose-dependent efficacy. Higher doses (10-15 mg) correlated with better retention, but gastrointestinal side effects (nausea, diarrhea) caused 6-10% dropout. Long-term use appears essential for sustainment.
Semaglutide: Insights from STEP 1 and Extension
The STEP 1 trial (NCT03548935) by John Wilding et al. tested semaglutide 2.4 mg weekly vs. placebo in 1,961 obese adults over 68 weeks. Semaglutide yielded 14.9-17.3% weight loss (vs. 2% placebo), with 86% achieving ≥5% loss.
The extension followed to week 120 (52 weeks post-discontinuation). The semaglutide group regained 11.6% of body weight from their nadir, while placebo regained 1.9%. Net loss at week 120: ~7% vs. baseline—half erased.
Deep dive: Regain was progressive, driven by returning appetite and reduced energy expenditure. Women regained more than men, per subgroup analysis.
